Sugi Predict

Sugi Predict / Compounds / SCHEMBL20766210

SCHEMBL20766210

SCHEMBL20766210

CNS(=O)(=O)c1ccc(NC2CCCCC2)c(-c2nnn(C)n2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 3/20 0.41
▸ CHEK1 O14757 1/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ MET P08581 1/20 0.39
▸ PIM1 P11309 1/20 0.39
▸ LTK P29376 1/20 0.39
▸ GRK5 P34947 1/20 0.39
▸ MAP2K2 P36507 1/20 0.39
▸ CDK8 P49336 1/20 0.39
▸ NEK2 P51955 1/20 0.39
▸ LIMK1 P53667 1/20 0.39
▸ TYRO3 Q06418 1/20 0.39
▸ MAP4K2 Q12851 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ AURKB Q96GD4 1/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ YAP1 P46937 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20767240 0.89 BRD4 (0.52) BRD4YAP1KMT2A
SCHEMBL20766328 0.88 BRD4 (0.43) BRD4CHEK1NTRK1METPIM1
SCHEMBL20766257 0.88 BRD4 (0.38) BRD4CHEK1NTRK1METPIM1
SCHEMBL30410841 0.88 BRD4 (0.38) BRD4CHEK1NTRK1METPIM1
SCHEMBL20766252 0.88 BRD4 (0.38) BRD4CHEK1NTRK1METPIM1
SCHEMBL20766234 0.87 ALDH1A1 (0.43) BRD4CHEK1NTRK1METPIM1
SCHEMBL20766876 0.87 BRD4 (0.38) BRD4CHEK1NTRK1METPIM1
SCHEMBL20766226 0.87 BRD4 (0.38) BRD4CHEK1NTRK1METPIM1
SCHEMBL20766378 0.87 ALDH1A1 (0.50) BRD4CHEK1NTRK1METPIM1
SCHEMBL30411281 0.87 BRD4 (0.38) BRD4CHEK1NTRK1METPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024092116-A1 COMBINATION OF TEAD INHIBITORS AND EGFR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2024-05-02 — — WO disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed
CN-111542315-B Benzosulfonyl compounds 维瓦斯治疗公司 2023-05-12 — — CN disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 — — US disclosed
EP-3691623-B1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS INC (US) 2022-10-05 — — EP disclosed
WO-2022187518-A1 SUBSTITUTED 4-PIPERIDINYL-IMIDAZO[4,5-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Ikena Oncology, Inc. (US) 2022-09-09 — — WO disclosed
WO-2022120355-A1 TEAD DEGRADERS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-06-09 — — WO disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed
WO-2020243423-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 — — US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 — — US disclosed
CN-111542315-A Benzosulfonyl compounds 维瓦斯治疗公司 2020-08-14 — — CN disclosed
EP-3691623-A1 BENZOSULFONYL COMPOUNDS Vivace Therapeutics, Inc. (US) 2020-08-12 — — EP disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 — — WO disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 BRD4 155/4885CHEK1 513/4885NTRK1 4215/4885
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 BRD4 155/4885CHEK1 513/4885NTRK1 4215/4885
US-11192865-B2 Benzosulfonyl compounds YAP1, TEAD2, TEAD1 BRD4 7/4885CHEK1 204/4885NTRK1 4221/4885
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 BRD4 328/4885CHEK1 3705/4885NTRK1 3196/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 BRD4 155/4885CHEK1 513/4885NTRK1 4215/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 BRD4 155/4885CHEK1 513/4885NTRK1 4215/4885
US-20200354325-A1 BENZOSULFONYL COMPOUNDS YAP1, TEAD2, TEAD1 BRD4 7/4885CHEK1 204/4885NTRK1 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.